Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome

Haematologica

Volumn 90, Issue 2, 2005, Pages 232-237

  De Souza, Carmino Antonio ^a   Vigorito, Afonso Celso ^a   Ruiz, Milton Artur ^b   Nucci, Márcio ^c   Dulley, Frederico Luiz ^d   Funcke, Vaneusa ^e   Tabak, Daniel ^f   Azevedo, Alexandre Mello ^f   Byington, Rita ^f   Macedo, Maria Cristina ^d   Saboya, Rosaura ^d   Aranha, Francisco José Penteado ^a   Oliveira, Gislaine Barbosa ^a   Zulli, Roberto ^a   Miranda, Eliana Cristina Martins ^a   Azevedo, Wellington Moraes ^g   Lodi, Fernanda Maria ^g   Voltarelli, Júlio Cesar ^d   Simões, Belinda Pinto ^d   Colturato, Vergĩlio ^h   De Souza, Mair Pedro ^h   Silla, Lũcia ⁱ   Bittencourt, Henrique ⁱ   Piron Ruiz, Lilian ^b   Maiolino, Angelo ^c   Gratwohl, Alois ^j   Pasquini, Ricardo ^e   more..

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b S Jose do Rio Preto Med Sch SP   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^f INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^g FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^h Jaú Cancer Hospital SP   (Brazil)

ⁱ FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^j UNIVERSITY HOSPITAL BASEL   (Switzerland)

more..

Author keywords

Allogeneic hematopoietic stem cell transplantation (HSCT); Chronic myeloid leukemia; EBMT risk scores

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; IMATINIB; MELPHALAN; METHOTREXATE;

ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BRAZIL; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CHILD; CHRONIC MYELOID LEUKEMIA; DEVELOPING COUNTRY; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; MAJOR CLINICAL STUDY; MALE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BRAZIL; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK; SEX FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 20044369703     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood 2001;98:2039-42.
2. Goldman JM. Therapeutic strategies for chronic myeloid leukemia in the chronic (stable) phase. Semin Hematol 2003;40:10-7.
3. Goldman JM, Marin D. Management decisions in chronic myeloid leukemia. Semin Hematol 2003;40:97-103.
4. Goldman JM, Marin D, Olavarria E, Apperley JF. Clinical decisions for chronic myeloid leukemia in the imatinib era. Semin Hematol 2003;40:98-113.
5. Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management or patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:1637-47.
6. Peggs K, Mackinnon S. Imatinib mesylate - the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003;348:1048-50.
7. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
8. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. International STI571 CML Study Group. N Engl J Med 2002;346: 645-52.
9. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99:1928-37.
10. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99:3530-9.
11. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994-1004.
12. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. International Randomised Study of Interferon versus STI571 (IRIS) Study Group. N Engl J Med 2003;349:1423-32.
13. Bhatia R, Holtz M, Niu N, Gray R, Shyder DS, Sawyers CL, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003;101: 4701-7.
14. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
15. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25.
16. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002;99:3472-5.
17. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16:2190-6.
18. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102:276-83.
19. Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Bensinger WI, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986;104:155-63.
20. Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AW, Batchelor R, et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1986;314:202-7.
21. Barrett AJ, Malkovska V. Graft-versus-leukaemia: understanding and using the alloimmune response to treat haematological malignancies. Br J Haematol 1996;93:754-61.
22. Passweg JR, Walker I, Sobocinski KA, Klein JP, Horowitz MM, Giralt SA. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol 2004;125; 613-20.
23. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998;352:1087-92.
24. Speck B, Bortin MM, Champlin R, Goldman JM, Herzig RH, McGlave PB, et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1984;1:665-8.
25. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103:2873-8.
26. Pulcheri W, Spector N, Nucci M, de Morais JC, Pimenta G, de Oliveira HP. The treatment of acute myeloid leukemia in Brazil: progress and obstacles. Haematologica 1995;80: 130-5.